Skip Navigation


Annals of Oncology Advance Access originally published online on February 13, 2008
Annals of Oncology 2008 19(5):898-902; doi:10.1093/annonc/mdm606
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: part 8 iss...
Right arrow All Versions of this Article:
19/5/898    most recent
mdm606v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Ann Oncol
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Barrett, S. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barrett, S. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

gynecologic tumors

Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial

S. V. Barrett1,*, J. Paul2, A. Hay2, P. A. Vasey3, S. B. Kaye4, R. M. Glasspool On behalf of the Scottish Gynaecological Cancer Trials Group1

1 Department of Medical Oncology, Beatson West of Scotland Cancer Centre, Glasgow
2 Cancer Research UK Clinical Trials Unit, Beatson West of Scotland Cancer Centre, Glasgow, UK
3 Department of Medical Oncology, University of Queensland, Brisbane, Australia
4 Section of Medicine, The Institute of Cancer Research, London, UK

* Correspondence to: Dr S. V. Barrett, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow G12 0YN, UK. Tel: +44-141-301-7000; Fax: +44-141-301-7124; E-mail: sophie.barrett{at}nhs.net

Background: Previous studies have indicated an association between obesity and poor survival in several tumour types, including ovarian cancer. We sought to test the hypothesis that obesity reduces survival in a large, well-characterised and relatively homogeneous cohort of ovarian cancer patients.

Patients and methods: The relationship between body mass index (BMI) and overall survival (OS) and progression-free survival (PFS) in 1067 patients participating in the Scottish Randomised Trial in Ovarian Cancer I trial was assessed. All patients received first-line carboplatin/taxane chemotherapy. The dose of carboplatin was determined by a measured glomerular filtration rate (GFR), ensuring accurate dosing in all categories of BMI and the dose of taxane was not capped. Patients were assigned to one of four categories: underweight (BMI < 18.5), ideal weight (BMI 18.5–24.9), overweight (BMI 25–29.9) or obese (BMI ≥ 30).

Results: There were neither statistically significant differences in PFS or OS between these four groups nor were there any differences in taxane or carboplatin dose intensity. Furthermore, there was no association between BMI and tumour stage or grade at presentation, or completeness of debulking surgery.

Conclusions: Obese patients with epithelial ovarian cancer do not have a poorer prognosis, provided that they receive optimal doses of chemotherapy based on measured GFR and actual body weight.

Key words: body mass index, ovarian cancer, survival

Received for publication October 4, 2007. Revision received December 18, 2007. Accepted for publication December 19, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Ann Oncol:

In this issue

Ann Oncol 2008 19: 827. [Extract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
S. R. McWhinney, R. M. Goldberg, and H. L. McLeod
Platinum neurotoxicity pharmacogenetics
Mol. Cancer Ther., January 1, 2009; 8(1): 10 - 16.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.